Introduction {#s1}
============

Major depressive disorder (MDD) and bipolar disorder are among the most serious psychiatric disorders with high prevalence and illness-related disability ([@B1]--[@B3]). Despite growing evidence for the spectrum concept of mood disorders ([@B4]), and even with the advanced neuroimaging methods developed in recent years, the underlying pathophysiological mechanisms of depression remain poorly understood. Evidence across resting-state functional magnetic resonance (fMRI) studies consistently points to an impairment of large-scale resting-state brain networks in MDD rather than a disruption of discrete brain regions ([@B5]--[@B8]). Consistent with the neurobiological model of depression ([@B9]), numerous resting-state fMRI studies show decreased frontal cortex function and increased limbic system function in patients with MDD ([@B10]). Functional abnormalities in large-scale brain networks include hypoconnectivity within the frontoparietal network ([@B7]) and the reward circuitry, centered around the ventral striatum ([@B11]). Reduced functional connectivity in first-episode drug-naïve patients with MDD was also recently reported between the frontoparietal and cingulo-opercular networks ([@B12]). Moreover, hyperconnectivity of the default mode network ([@B13]) and amygdala hyperconnectivity with the affective salience network ([@B14], [@B15]) were shown to be characteristic features of depression.

In general, large-scale networks dynamically re-organize themselves on sub-second temporal scales to enable efficient functioning ([@B16], [@B17]). Fast temporal dynamics of large-scale neural networks, not accessible with the low temporal resolution of the fMRI technique, can be investigated by analyzing the temporal characteristics of "EEG microstates" ([@B18], [@B19]). Scalp EEG measures the electric potential generated by the neuronal activity in the brain with a temporal resolution in the millisecond range. A sufficient number of electrodes distributed over the scalp, i.e., high density-EEG (HD-EEG), allows for the reconstruction of a scalp potential map representing the global brain activity ([@B20]). Any change in the map topography reflects a change in the distribution and/or orientation of the active sources in the brain ([@B21]). Already in 1987 ([@B22]), Lehmann et al. observed that in spontaneous resting-state EEG, the topography of the scalp potential map remains stable for a short period of time and then rapidly switches to a new topography in which it remains stable again. Ignoring map polarity, the duration of these stable topographies is around 80--120 ms. Lehmann called these short periods of stability EEG microstates and attributed them to periods of synchronized activity within large-scale brain networks. For a recent review, see Ref. ([@B19]). Assessment of the temporal characteristics of these microstates provides information about the dynamics of large-scale brain networks, because this technique simultaneously considers signals recorded from all areas of the cortex. Since the temporal variation in resting-state brain network dynamics may be a significant biomarker of illness and therapeutic outcome ([@B23]--[@B25]), microstate analysis is a highly suitable tool for this purpose.

Numerous studies demonstrated changes in EEG microstates in patients with neuropsychiatric disorders such as schizophrenia, dementia, panic disorder, multiple sclerosis, and others \[for reviews see Refs. ([@B19], [@B26])\]. Despite the potential of microstate analysis for detecting global brain dynamic impairment, microstates were not investigated in depressive patients, except for three studies that provided inconsistent results. Using adaptive segmentation of resting state EEG in depressive patients, two early studies showed abnormal microstate topographies and reduced overall average microstate duration ([@B27]) but unchanged numbers of different microstates per second ([@B28]). In a more recent study using a topographical atomize-agglomerate hierarchical clustering algorithm, abnormally increased overall microstate duration and decreased overall microstate occurrence per second were reported in treatment-resistant depression ([@B29]).

A better understanding of disruption and changes in brain network dynamics in depression is critical for developing novel and targeted treatments, e.g., deep brain stimulation in treatment-resistant depression ([@B30]). Furthermore, microstate features reflecting the disruption of brain network dynamics might be later tested as candidate biomarkers of depressive disorder and predictors of treatment response. Thus, the main goal of our study was to explore how resting-state microstate dynamics are affected in depressive patients as compared to healthy individuals. We hypothesized that patients with depression will show different microstate dynamics than healthy controls in terms of the temporal characteristics of EEG microstates such as duration, coverage, and occurrence. We also hypothesized that microstate dynamics will be related to the overall clinical severity of depression.

Materials and Methods {#s2}
=====================

Subjects {#s2_1}
--------

Data was collected from 19 depressive patients (age in years: mean = 53.0, standard deviation = 9.8; 6 females) and 19 healthy control (HC) subjects (age in years: mean = 51.4, standard deviation = 9.1; 6 females). Education was classified into three levels: 1 = no high school, 2 = high school, 3 = university studies in the depressed (mean = 1.9, standard deviation = 0.9) and HC (mean = 2.2, standard deviation = 0.7) groups. There were no differences in gender, and an independent sample *t*-test also showed no significant differences in age \[*t*-value (df 36) = 0.45, *p* \> 0.05\] or education \[*t*-value (df 36) = −1.5, *p* \> 0.05\] between the two groups. The patients were recruited at the Department of Psychiatry, Faculty of Medicine, Masaryk University and University Hospital Brno. The diagnostic process had two steps and was determined based on the clinical evaluation by two board-certified psychiatrists. First, the diagnosis was made according to the criteria for research of the International Classification of Disorders (ICD-10). Second, the diagnosis was confirmed by the Mini International Neuropsychiatric interview (M.I.N.I.) according to the *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition* (DSM-V). All patients were examined in the shortest time period after the admission and before the stabilisation of treatment, typically during their first week of hospitalization. All patients met the criteria for at least a moderate degree of depression within the following affective disorders: bipolar affective disorder (F31), depressive episode (F32), and recurrent depressive disorder (F33). Exclusion criteria for patients were any psychiatric or neurological comorbidity, IQ \< 70, organic disorder with influence on the brain function, alcohol dependence, or other substance dependence. All patients were in the on-medication state with marked interindividual variability in specific medicaments received. The patient characteristics are summarized in [**Table 1**](#T1){ref-type="table"}. Control subjects were recruited by general practitioners from their database of clients. Control subjects underwent the M.I.N.I. by board-certified psychiatrists to ensure that they had no previous or current psychiatric disorder according to the DSM-V criteria. The scores on the Montgomery--Åsberg Depression Rating Scale (MADRS), a specific questionnaire validated for patients with mood disorders ([@B32]), and Clinical Global Impression (CGI) ([@B33]), a general test validated for mental disorders, were used to evaluate the severity of depressive symptoms in patients. The status of depression was further described with lifetime count of depressive episodes and illness duration in years. Medication in 24 h preceding the EEG examination was also recorded (see [**Table 1**](#T1){ref-type="table"}). This study was carried out in accordance with the recommendations of Ethics Committee of University Hospital Brno with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the Ethics Committee of University Hospital Brno, Czech Republic.

###### 

Patient characteristics.

  Patient   ICD-10 diagnose   Number of episodes   Illness duration (years)   MADRS score   CGI score   BZD    AD/AP/MS     Medication scale AD/AP/MS
  --------- ----------------- -------------------- -------------------------- ------------- ----------- ------ ------------ ---------------------------
  1         F31.4             3                    2                          27            4           2      AD, AP, MS   3
  2         F32.2             1                    0.5                        24            5           0      AD           2
  3         F32.1             1                    1                          15            4           2      AD           2
  4         F31.5             5                    20                         39            6           0      AP           2
  5         F33.1             3                    7                          18            4           0      AD           1
  6         F33.1             2                    8                          9             3           1.33   AD           1
  7         F32.1             1                    1                          24            4           1.33   AD, AP       3
  8         F31.4             4                    27                         29            5           2      AP           2
  9         F33.3             2                    5                          36            6           1      AD, AP       4
  10        F33.1             3                    19                         21            4           1      AD           1
  11        F33.3             2                    2                          38            5           6      AD, AP       4
  12        F33.2             2                    1                          39            5           3      AD, AP       4
  13        F32.3             1                    0.08                       21            5           2      AD, AP       4
  14        F33.2             5                    21                         32            5           0      AD, AP       3
  15        F33.3             2                    2                          38            6           3      AD, AP       4
  16        F32.3             1                    0.08                       37            6           2      AD, AP       4
  17        F33.1             3                    4                          18            4           0      AD, AP       4
  18        F31.3             2                    16                         28            4           0      AP, MS       4
  19        F31.3             11                   24                         23            4           1      AP, MS       4

F31.3, Bipolar affective disorder, current episode mild or moderate depression; F31.4, Bipolar affective disorder, current episode severe depression without psychotic symptoms; F31.5, Bipolar affective disorder, current episode severe depression with psychotic symptoms; F32.1, Moderate depressive episode; F32.2, Severe depressive episode without psychotic symptoms; F32.3, Severe depressive episode with psychotic symptoms; F33.1, Recurrent depressive disorder, current episode moderate; F33.2, Recurrent depressive disorder, current episode severe without psychotic symptoms; F33.3, Recurrent depressive disorder, current episode severe with psychotic symptoms; BZD, benzodiazepine equivalent dose ([@B31]); AD, antidepressants (mirtazapine, citalopram, venlafaxine, vortioxetine, sertraline); AP, antipsychotics (risperidone, olanzapine, quetiapine, amisulpride, aripiprazole); MS, mood stabilizers (valproate, lamotrigine); medication scale AD/AP/MS: 1, one medication in sub-therapeutic doses; 2, one medication in therapeutic doses; 3, combination of medications with one in therapeutic doses; 4, combination of medications with more than one in therapeutic doses; MADRS (Montgomery--Åsberg Depression Rating Scale): score is between 0 and 60, the higher the score the higher the depressive symptom severity; CGI (Clinical Global Impression) scale: healthy (1) -- most extremely ill (7). Four patients were undergoing the first (patient 3) and second (patients 4 and 9) week of electroconvulsive therapy and the first week of repetitive transcranial magnetic stimulation (patient 5). No clinical effect of these neurostimulation treatments was apparent.

EEG Recording and Pre-processing {#s2_2}
--------------------------------

Subjects were sitting in a comfortable upright position in an electrically shielded room with dimmed light. They were instructed to stay as calm as possible to keep their eyes closed and to relax for 15 min. They were asked to stay awake. All participants were monitored by the cameras, and in the event of signs of nodding off or EEG signs of drowsiness detected by online visual inspection, the recording was stopped. The EEG was recorded with a high density 128-channel system (EGI System 400; Electrical Geodesic Inc., OR, USA), a sampling rate of 1kHz, and Cz as acquisition reference.

Five minutes of the EEG data were selected based on visual assessment of the artifacts. The EEG was band-pass filtered between 1 and 40 Hz. Subsequently, in order to remove ballistocardiogram and oculo-motor artifacts, infomax-based Independent Component Analysis ([@B34]) was applied to all but one or two channels rejected due to abundant artifacts. Only components related to ballistocardiogram, saccadic eye movements, and eye blinking were removed based on the waveform, topography, and time course of the component. The cleaned EEG recording was down-sampled to 125 Hz, and the previously identified noisy channels were interpolated using a three-dimensional spherical spline ([@B35]) and re-referenced to the average reference. For subsequent analyses, the EEG data was reduced to 110 channels to remove muscular artifacts originating in the neck and face. All the preprocessing steps were done using the freely available Cartool Software 3.70, programmed by Denis Brunet Cartool (<https://sites.google.com/site/cartoolcommunity/home>) and MATLAB.

Microstate Analysis {#s2_3}
-------------------

The microstate analysis (see [**Figure 1**](#f1){ref-type="fig"}) followed the standard procedure using *k*-means clustering method to estimate the optimal set of topographies explaining the EEG signal ([@B36]--[@B38]). The polarity of the maps was ignored in this clustering procedure. To determine the optimal number of clusters, we applied a meta-criterion that is a combination of seven independent optimization criteria \[for details see Ref. ([@B39])\]. In order to improve the signal-to-noise ratio, only the data at the time points of the local maximum of the global field power (GFP) were clustered ([@B38], [@B40]--[@B42]). The GFP is a scalar measure of the strength of the scalp potential field and is calculated as the standard deviation of all electrodes at a given time point ([@B36], [@B37], [@B43]). The cluster analysis was first computed at the individual level and then at global level across all participants (patients and controls).

![Microstate analysis: **(A)** resting-state EEG from subsample of 16 out of 110 electrodes; **(B)** global field power (GFP) curve with the GFP peaks (vertical lines) in the same EEG period as shown in **(A)**; **(C)** potential maps at successive GFP peaks, indicated in **(B)**, from the first 1 s period of the recording; **(D)** set of six cluster maps best explaining the data as revealed by K-means clustering of the maps at the GFP peaks; **(E)** the original EEG recording shown in **(A)** with superimposed color-coded microstate segments. Note that each time point of the EEG recording was labelled with the cluster map, shown in **(D)**, with which the instant map correlated best. The duration of segments, occurrence, and coverage for all microstates were computed on thus labeled EEG recording.](fpsyt-10-00548-g001){#f1}

Spatial correlation was calculated between every map identified at the global level and the individual subject's topographical map in every instant of the pre-processed EEG recording. Each continuous time point of the subject's EEG (not only the GFP peaks) was then assigned to the microstate class of the highest correlation, again ignoring polarity ([@B19], [@B36], [@B39], [@B44]). Temporal smoothing parameters \[window half size = 3, strength (Besag Factor) = 10\] ensured that the noise during low GFP did not artificially interrupt the temporal segments of stable topography ([@B36], [@B38]). For each subject, three temporal parameters were then calculated for each of the previously identified microstates: i) occurrence, ii) coverage, and iii) duration. Occurrence indicates how many times a microstate class recurs in 1 s. The coverage represents the summed amount of time spent in a given microstate class. The duration in milliseconds for a given microstate class indicates the amount of time that a given microstate class is continuously present. In order to assess the extent to which the representative microstate topographies explain the original EEG data, the global explained variance (GEV) was calculated as the sum of the explained variances of each microstate weighted by the GFP. Microstate analysis was performed using the freely available Cartool Software 3.70, programmed by Denis Brunet Cartool (<https://sites.google.com/site/cartoolcommunity/home>).

Statistical Analysis {#s2_4}
--------------------

To investigate group differences, independent *t*-tests were used for temporal parameters of each microstate. Comparisons were corrected using the false discovery rate (FDR) method ([@B45]). In order to evaluate the possible relation of microstate dynamics to severity of depression, we computed Spearman's rank correlation coefficients of all microstate parameters with the MADRS and CGI scores and number of episodes. In order to evaluate possible influence of medication on microstate dynamics, we calculated Spearman's rank correlation coefficients between all microstate parameters and medication that patients received during 24 h preceding the EEG measurement. Intake of antidepressants, antipsychotics, and mood stabilizers was indicated as a single ordinal variable taking into account the number of medicaments and their dosages. Intake of benzodiazepines was expressed with the benzodiazepine equivalent dose ([@B33]). A significance level of α \< 0.01 was used for all correlations. Statistical evaluation of the results was performed by the routines included in the program package Statistica'13 (1984-2018, TIBCO, Software Inc, Version 13.4.0.14).

Results {#s3}
=======

The meta-criterion used to determine the most dominant topographies revealed six microstates explaining 82.6% of the global variance. Four topographies resembled those previously reported in the literature as A, B, C, and D maps ([@B19], [@B29], [@B40], [@B41]) and two topographies resembled the recently identified ([@B46]) resting-state microstate maps. We labeled these maps as A--D, in accordance with previous literature, and as E and F ([**Figure 2**](#f2){ref-type="fig"}).

![The six microstate topographies identified in the global clustering across all subjects.](fpsyt-10-00548-g002){#f2}

The groups did not differ in any temporal parameter in any microstate. The depressive group was indistinguishable from the control group (all absolute *t*-values \< 2.5). The FDR-corrected *p*-values (six comparisons for the six microstate classes) were not significant between the patients and controls for any microstate in the duration (A: *p* = 0.39; B: *p* = 0.39; C: *p* = 0.30; D: *p* = 0.39; E: *p* = 0.77; F: *p* = 0.68), occurrence (A: *p* = 0.13; B: *p* = 0.92; C: *p* = 0.92; D: *p* = 0.92; E: *p* = 0.13; F: *p* = 0.29), or coverage (A: *p* = 0.44; B:*p* = 0.75; C:*p* = 0.44; D: *p* = 0.75; E:*p* = 0.16; F: *p* = 0.44).

The results of Spearman's rank correlation revealed a positive association of the depression severity with the presence of microstate A but not with the presence of other microstates. The occurrence of microstate A significantly correlated with the MADRS scores (*r* = 0.70, *p* \< 0.01; [**Figure 3**](#f3){ref-type="fig"}), but not with the CGI score (*r* = 0.40), illness duration (*r* = 0.06), or the number of episodes (*r* = 0.08). There were no significant associations between the depression severity and the duration or coverage of microstate A (all absolute *r*-values \< 0.55).

![Correlation between the occurrence of microstate A and Montgomery--Åsberg Depression Rating Scale (MADRS) score.](fpsyt-10-00548-g003){#f3}

The results of Spearman's rank correlation revealed a significant positive association between the medication status and the presence of microstate E but not with the presence of other microstates. The occurrence of microstate E significantly correlated with the intake of antidepressants, antipsychotics, and mood stabilizers (*r* = 0.65, *p* \< 0.01; [**Figure 4**](#f4){ref-type="fig"}), but not with the intake of benzodiazepines (*r* = 0.20). There were no significant associations between the medication status and the duration or coverage of microstate E (all absolute *r*-values \< 0.45).

![Correlation between the occurrence of microstate E and the intake of antidepressants, antipsychotics, and mood stabilizers. Medication scale: 1, one medication in sub-therapeutic doses; 2, one medication in therapeutic doses; 3, combination of medications with one in therapeutic doses; 4, combination of medications with more than one in therapeutic doses.](fpsyt-10-00548-g004){#f4}

Discussion {#s4}
==========

In this report, the dynamics of resting-state large-scale brain network activity are depicted in the form of functional EEG brain microstates. We demonstrated that microstate temporal dynamics are sensitive to interindividual differences in depressive symptom severity in patients with moderate to severe depression. Particularly, we showed that severity of depressive symptoms correlated with higher occurrence of the microstate A. This finding suggests that microstate analysis-based neural markers might represent a largely untapped resource for understanding the neurobiology of depression. Since the between-group differences were absent in EEG dynamic, it is, however, unknown, if higher occurrence of microstate A is a complex expression of depressive symptomatology or if it reflects a latent risk factor. The here demonstrated symptom-related interindividual differences in microstate dynamics need further research to test its utility in an objective depression assessment. The present study is the first in a planned longitudinal study series with depressive patients recruited at the University Hospital Brno that will help further investigate the microstate parameters as possible predictors of treatment response to both medication and neurostimulation methods including the electroconvulsive therapy.

Only three studies examined microstate duration and/or occurrence in depressive patients. The earliest study showed lower duration in the depressive group than in controls ([@B27]). In a subsequent study, between-group differences in occurrence were found neither in young nor aged depressive patients as compared to healthy controls ([@B28]). Contrary to these early findings, longer duration and lower occurrence of microstates in treatment-resistant depressed patients as compared to healthy subjects were demonstrated recently ([@B29]). The authors suggested that the increased duration and decreased occurrence in microstates could reflect modulation of global brain dynamics with neurotropic medications previously taken by patients resistant to antidepressant treatment. In the current study, we found an increased microstate A occurrence with depression only as an effect related to the symptom severity and not as a between-group difference. This finding is, despite different analytical approaches used in the studies, consistent with the previously reported lowering of microstate occurrence following magnetic seizure therapy and electroconvulsive therapy that in fact might represent a normalization of occurrence with successful treatment ([@B29]).

Different methodological approaches might have, however, led to discrepant findings in terms of duration of microstates among the current and the three previous studies. The methodological differences include different frequency bands examined ([@B28]), different clustering algorithms applied ([@B27]--[@B29]), different numbers of maps used for backfitting to the EEG ([@B29]), and analyzing all data points (e.g., in current study) or only those with the local maxima of the global field power \[e.g., in Ref. ([@B29])\].

Discrepant findings may also reflect the pathophysiologic heterogeneity of depression. Similarly to the current sample, the experimental group in the study by Strik et al. ([@B27]) included depressive patients who met the criteria for unipolar or bipolar mood disorders or for dysthymia. The other two studies both focused on unipolar depression ([@B28], [@B29]), the more recent one was even restricted only to the treatment-resistant form of depression ([@B29]). With respect to the symptom variations in patients meeting criteria for depression, currently based solely on the clinical interviews and diagnostic questionnaires, such heterogeneity in findings could be expected.

In the current study, the topography of microstate A strongly resembled the topography of one of the four canonical microstates, i.e., microstate A, earlier described in the literature ([@B19], [@B26]). Using resting-state fMRI, this microstate was previously linked to the auditory brain network ([@B41]), involving bilateral superior and middle temporal gyri, regions associated with phonological processing ([@B47]). In addition to this indirect identification of involved brain structures, the sources generating microstate scalp topographies were directly estimated ([@B39], [@B46]). The left temporal lobe and left insula were identified as the major generators of microstate A ([@B47]). Additionally, left-lateralized activity in the medial prefrontal cortex and the occipital gyri was most recently reported to underlie this microstate ([@B39]).

Evidence from the meta-analysis of functional neuroimaging studies suggests resting-state functional alterations in first-episode drug-naïve MDD patients in the fronto-limbic system, including the dorsolateral prefrontal cortex and putamen, and in the default mode network, namely, the precuneus and superior and middle temporal gyri ([@B48]). Altered activity in the superior temporal gyrus in patients with MDD was reported repeatedly in fMRI studies ([@B49]--[@B52]) and was also suggested to be responsible for the abnormal processing of negative mood and cognition in first-episode, drug-naïve patients with MDD ([@B48]). Our findings of positive associations of depressive symptoms with the occurrence of microstate A that is related to temporal lobe activity are thus in line with these studies.

It has been shown that benzodiazepines and antipsychotics may modulate microstate dynamics ([@B53]). Accordingly, we observed the effect of medication on the presence of microstate E. The topography of this microstate strongly resembled one of the newly reported microstates, the generators of which were identified in the dorsal anterior cingulate cortex, superior and middle frontal gyri, and insula ([@B46]). The cingulo-opercular network (CON), comprising regions in the thalamus as well as frontal operculum/anterior insula and anterior cingulate cortex, is considered to have a central role in sustaining alertness ([@B54]) or in general for maintaining perceptual readiness ([@B55]). An important role in the pathophysiological mechanisms of depression was suggested for the CON, whose disrupted functional connectivity was observed in first-episode drug-naïve patients with MDD ([@B12]). Since the medication status in our study was only roughly defined, it is rather questionable whether the observed correlation between the medication scoring and the occurrence of microstate E could be related to the pharmacological effect on the activity of structures constituting the CON.

In the current study, we decided to use the resting-state condition rather than employing any cognitive task. Depression affects not only emotional and cognitive mental operations but also motivational processes. Therefore, the task performance differences between patients and healthy controls may relate to different levels of motivation rather than information processing per se. Using a resting-state condition makes it possible to avoid some task-related confounds and makes the application of non-invasive neuroimaging techniques a powerful tool for measuring baseline brain activity ([@B56]). Moreover, if the research outputs such as those presented here lead to developing a new diagnostic tool for depressive disorder, such a tool, based on evaluating the resting-state scalp EEG, will be easy to use and require only minimal cooperation from the patients.

It is important to note that our data may have limitations. First, our sample included mixed diagnoses, with both bipolar and unipolar disorders. The observed relationship between the microstate A occurrence and depressive symptomatology should therefore be considered as a state rather than as a trait marker of depression. Second, the low sample size and great variability in medication made it impossible to examine any potential influence of medication on the microstate parameters by comparing patients receiving a specific drug with those not receiving it. To summarize the various medications, an ordinal variable was used that is only a rough measurement of medication usage. Therefore, the observed relationship between the microstate E occurrence and medications should be viewed with caution.

Conclusions {#s5}
===========

The study presented here provides insights into global brain dynamics of the resting-state in depressive patients. The identified depressive symptom-related changes in resting-state large-scale brain dynamics suggest the utility of the microstate analysis approach in an objective depression assessment. On the other side, using this analysis at the individual level could prove challenging. To test the observed microstate changes as possible biomarkers of illness and/or treatment response at individual level is the next step for future research in depressive patients.
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